adiponectin, diabetes and ischemic heart failure a challenging relationship脂联素、糖尿病和缺血性心力衰竭具有挑战性的关系.pdfVIP

Baldasseroni et al. Cardiovascular Diabetology 2012, 11:151 CARDIO /content/11/1/151 VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Adiponectin, diabetes and ischemic heart failure: a challenging relationship Samuele Baldasseroni1,2*, Alessandro Antenore1,2, Claudia Di Serio1,2, Francesco Orso1,2, Giuseppe Lonetto1,2, Nadia Bartoli1,2, Alice Foschini1,2, Andrea Marella1,2, Alessandra Pratesi1,2, Salvatore Scarantino1,2, Stefano Fumagalli1,2, Matteo Monami1,2, Edoardo Mannucci1,2, Niccolò Marchionni1,2 and Francesca Tarantini1,2 Abstract Background: Several peptides, named adipokines, are produced by the adipose tissue. Among those, adiponectin (AD) is the most abundant. AD promotes peripheral insulin sensitivity, inhibits liver gluconeogenesis and displays anti-atherogenic and anti-inflammatory properties. Lower levels of AD are related to a higher risk of myocardial infarction and a worse prognosis in patients with coronary artery disease. However, despite a favorable clinical profile, AD increases in relation to worsening heart failure (HF); in this context, higher adiponectinemia is reliably related to poor prognosis. There is still little knowledge about how certain metabolic conditions, such as diabetes mellitus, modulate the relationship between AD and HF. We evaluated the level of adiponectin in patients with ischemic HF, with and without type 2 diabetes, to elucidate whether the metabolic syndrome was able to influence the relationship between AD and HF. Results: We demonstrated that AD rises in patients with advanced HF, but to a lesser